Previous Study: TRIO025
Next Study: TRIO029

Studies & Results


A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab


SABCS, 2013

Slamon D, Swain S, Buyse M, et al.

Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at